We acknowledge Salom LeibundGut-Landmann (Section of Immunology, Vetsuisse-Faculty, University of Zurich) for providing the 101 strain
10.3389/fimmu.2019.02247 4 Ait-OmarA.Monteiro-SepulvedaM.PoitouC.Le GallM.CotillardA.GiletJ.et al (2011)
Last month (May 2025), Novo Nordisk and Septerna, a San Francisco, California-based bio/pharmaceutical company focused on GCPRs, formed an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small-molecule medicines for treating obesity, Type 2 diabetes, and other cardiometabolic diseases, in a deal worth up to $2.2 billion ($200 million upfront and near-term funding and $2 billion in milestone payments)
However, there are more stringent rules (rules that must be followed carefully without exceptions) for insulin-dependent Type 1 diabetics